Local Innovation, Commercialization and Security
Leading the Way
The Delaware Valley BiopharmaceuticaL Hub for Enterprises, Local Innovation, Commercialization and Security (DBLHELICS) TechHub will ensure U.S. leadership in biopharma manufacturing by developing domestic talent, attracting capital to the Greater Philadelphia Region, and by setting an example for regions throughout the U.S.
Investing in our future
Biopharmaceuticals are revolutionizing medicine. Manufacturing these treatments is challenging as they rely on living cells for their production, but they help save, sustain, and improve lives. Biopharmaceutical production requires advanced manufacturing and technologies to assure the identity, purity, and potency of the final product. These medicines treat and prevent some of the most significant and debilitating diseases including autoimmune disorders, cancers, and viral infections.
The Delaware Valley BiopharmaceuticaL Hub for Enterprises, Local Innovation, Commercialization and Security (DBLHELICS) is a consortium representing the intersection of government priorities, existing regional assets, resources and capabilities, and an industry with projected significant global growth.
The potential of the region for global competitiveness
%
Global Biopharma Market Annual Growth Rate
The global biopharma market was about $343 billion in 2021 and is expected to reach $719 billion by 2030 with an annual growth rate of 7.8%.
Strong Capital Investment
The biopharma industry was #1 among R&D-intensive industries for capital investment in 2018.
Opportunity to grow domestic supply chains
The U.S. trade balance in biopharmaceuticals went from neutral in 2000 to an $85 billion deficit by 2020.
Supports Over 4 Million Jobs Across the Country
The overall biopharma industry has a workforce of 900,000 total direct jobs supporting a total of 4.4 million jobs including supply chains.
SOURCE: Emergen: 2021 Press Release | Walsh and Walsh: Biopharmaceutical Benchmarks 2022 | Pharmaceutical Research & Manufacturers of America (2022) | Ezell (2021). Going, Going, Gone? To Stay Competitive in Biopharma, America Must Learn From Its Semiconductor Mistakes.
DBLHELICS Regional Partnerships
DBLHELICS will coordinate and leverage existing regional partnerships across DE/NJ/PA borders, and create a diverse workforce of individuals with well-paying jobs. It will leverage the region’s venture community, capital, and industry best practices to move products from lab-to-market and will create a globally competitive region within 10 years that:
Leveraging Resources
Promoting Workforce Development
Supporting National Competitiveness
DBLHELICS includes partners from the Philadelphia-Camden-Wilmington the adjacent Dover, DE, and Salisbury, MD-DE MSAs: a region hosting diverse individuals, opportunities, and companies, representative of the U.S. at large. Emphasizing workforce development initiatives, DBLHELICS’ outcomes will be scalable to rural, suburban, and urban locations across the U.S., maximizing this TechHub’s national impact.
Discover the Power of DBLHELICS
Learn how local resources, capabilities and partnerships are poised for remarkable biopharmaceutical global expansion. Connect with us today!
ADDRESS
590 Avenue 1743
Newark, DE 19713 U.S.A.